Anumana’s AI tool for pulmonary hypertension gets FDA breakthrough status
Related Articles
Anumana Entered into a Multi-Year Strategic Collaboration with Novartis to Develop ECG AI Algorithms for the Detection of Heart Disease
PharmaShots: The companies collaborated to develop & deliver new medical device software i.e., ECG AI algorithms for earlier detection of heart disease. The AI will screen for atherosclerotic CV disease…{post_date: F d, Y}
Anumana and InfoBionic.Ai Announce Collaboration to Advance AI-powered Remote Cardiac Telemetry Technology for Early Detection of Cardiac Diseases
Anumana and InfoBionic.Ai Announce Collaboration to Advance AI-powered Remote Cardiac Telemetry Technology for Early Detection of Cardiac Diseases CAMBRIDGE, Mass. – June 25, 2024 – Anumana, a leading AI-driven health…{post_date: F d, Y}
Anumana Receives U.S. FDA Breakthrough Device Designation for its Cardiac Amyloidosis Algorithm
DAIC: Anumana, Inc., a leading AI-driven health technology company, has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its ECG-AI algorithm designed to aid the…{post_date: F d, Y}
AI researchers at Mayo Clinic use the Apple Watch to detect silent, weakening heart disease
FIERCE Biotech: Using simplified ECG data taken from an Apple Watch, researchers at the Mayo Clinic were able to use an artificial intelligence algorithm to spot people whose hearts may…{post_date: F d, Y}